The FDA has approved an investigational new drug application for Tumor Paint BLZ-100, a protein-linked dye that highlights cancer cells in images so surgeons can precisely target brain tumors.The FDA move means Blaze Bioscience can proceed with clinical trials.

Twenty-one adult patients who need surgery for often-deadly glioma brain tumors are expected to enroll in the study, which is aimed at examining the safety of injecting the BLZ-100 molecule into the bloodstream, where it rushes to highlight cancer cells.